Effects of denosumab on fracture and bone mineral density by level of kidney function.

@article{Jamal2011EffectsOD,
  title={Effects of denosumab on fracture and bone mineral density by level of kidney function.},
  author={Sophie A. Jamal and Osten Ljunggren and Catherine O. Stehman-Breen and Steve Cummings and Michael R Mcclung and Stefan Goemaere and Peter R. Ebeling and Edward Franek and Yin Yang and Ogo I Egbuna and Steven Boonen and Paul Eugene Miller},
  journal={Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research},
  year={2011},
  volume={26 8},
  pages={
          1829-35
        }
}
The incidences of osteoporosis and chronic kidney disease (CKD) both increase with increasing age, yet there is a paucity of data on treatments for osteoporosis in the setting of impaired kidney function. We examined the efficacy and safety of denosumab (DMAb) among subjects participating in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Study. We estimated creatinine clearance (eGFR) using Cockcroft-Gault and classified levels of kidney function using… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 86 CITATIONS, ESTIMATED 52% COVERAGE

174 Citations

0102030'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 174 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…